Phase 3 randomized double-blind study evaluating selinexor, an XPO1 inhibitor, plus ruxolitinib in JAKi-naive myelofibrosis.

被引：0
|
作者：
Mascarenhas, John
Maher, Keri Renee
Rampal, Raajit
Bose, Prithviraj
Podoltsev, Nikolai Alexandrovich
Hong, Junshik
Wang, Xulong
Kye, Steve
Harrison, Claire
机构：
[1] Icahn Sch Med Mt Sinai, New York, NY USA
[2] VCU Massey Comprehens Canc Ctr, Richmond, VA USA
[3] Mem Sloan Kettering Canc Ctr, Dept Med, Leukemia Serv, New York, NY USA
[4] Univ Texas MD Anderson Canc Ctr, Dept Leukemia, Houston, TX USA
[5] Yale Sch Med, New Haven, CT USA
[6] Seoul Natl Univ, Seoul Natl Univ Hosp, Dept Internal Med, Coll Med, Seoul, South Korea
[7] Karyopharm Therapeut, Newton, MA USA
[8] Guys & St Thomas NHS Fdn Trust, Dept Haematol, London, England
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS6594
引用
收藏
页数：1
相关论文
共 50 条
  • [21] MANIFEST-2, A GLOBAL, PHASE 3, RANDOMIZED, DOUBLE-BLIND, ACTIVE-CONTROL STUDY OF CPI 0610 AND RUXOLITINIB VS. PLACEBO AND RUXOLITINIB IN JAK INHIBITOR-TREATMENT-NAIVE MYELOFIBROSIS PATIENTS
    Passamonti, F.
    Palandri, F.
    Mascarenhas, J.
    Harrison, C.
    Patriarca, A.
    Vannucchi, A.
    Luptakova, K.
    Wang, J.
    Colak, G.
    Shao, J.
    Bobba, S.
    Trojer, P.
    Humphrey, J.
    Verstovsek, S.
    HAEMATOLOGICA, 2021, 106 (10) : 81 - 82
  • [22] A Phase 1, open-label, dose-escalation study of selinexor plus ruxolitinib in patients with treatment-naive myelofibrosis
    Ali, Haris
    Kishtagari, Ashwin
    Maher, Keri
    Mohan, Sanjay
    Ansaldo, Karen
    Wang, Xulong
    Chamoun, Kamal
    Prchal, Josef T.
    Tantravahi, Srinivas K.
    CANCER RESEARCH, 2023, 83 (08)
  • [23] A Phase 1, Open-Label, Dose-Escalation Study of Selinexor Plus Ruxolitinib in Patients with Treatment-Naive Myelofibrosis
    Ali, Haris
    Kishtagari, Ashwin
    Maher, Keri
    Mohan, Sanjay R.
    Ansaldo, Karen
    Wang, Xulong
    Chamoun, Kamal
    Prchal, Josef T.
    Tantravahi, Srinivas K.
    BLOOD, 2022, 140 : 3986 - 3987
  • [24] PHASE 3 RANDOMIZED TRIAL OF MOMELOTINIB VERSUS RUXOLITINIB IN JAK INHIBITOR NAIVE PATIENTS WITH MYELOFIBROSIS: RESULTS OF THE SIMPLIFY-1 STUDY
    Gotlib, J. R.
    Kiladjian, J-J.
    Catalano, J. V.
    Devos, T.
    Egyed, M.
    Hellman, A.
    McLornan, D. P.
    Shimoda, K.
    Winton, E. F.
    Deng, W.
    Dubowy, R. L.
    Maltzman, J. D.
    Cervantes, F.
    Mesa, R. A.
    HAEMATOLOGICA, 2017, 102 : 320 - 320
  • [25] Randomized, double-blind, phase two study of ruxolitinib plus regorafenib in patients with relapsed/refractory metastatic colorectal cancer
    Fogelman, David
    Cubillo, Antonio
    Garcia-Alfonso, Pilar
    Limon Miron, Maria Luisa
    Nemunaitis, John
    Flora, Daniel
    Borg, Christophe
    Mineur, Laurent
    Vieitez, Jose M.
    Cohn, Allen
    Saylors, Gene
    Assad, Albert
    Switzky, Julie
    Zhou, Li
    Bendell, Johanna
    CANCER MEDICINE, 2018, 7 (11): : 5382 - 5393
  • [26] A randomized, double-blind study of zinpentraxin alfa in patients with myelofibrosis who were previously treated with or ineligible for ruxolitinib: stage 2 of a phase II trial
    Verstovsek, Srdan
    Talpaz, Moshe
    Wadleigh, Martha
    Isidori, Alessandro
    te Boekhorst, Peter
    Savona, Michael R.
    Bose, Prithviraj
    Pozdnyakova, Olga
    Mesa, Ruben
    El-Galaly, Tarec C.
    O'Sullivan, Jennifer
    Gamel, Katia
    Higgins, Brian
    Katakam, Sudhakar
    Todorov, Boyan
    Trunzer, Kerstin
    Harrison, Claire N.
    HAEMATOLOGICA, 2024, 109 (06) : 1977 - 1983
  • [27] Pelabresib Plus Ruxolitinib Combination Therapy in JAK Inhibitor-Naive Patients With Myelofibrosis in the Phase 3 MANIFEST-2 Study: Preliminary Evidence of Bone Marrow Recovery
    Mascarenhas, John
    Rampal, Raajit K.
    Vannucchi, Alessandro M.
    Gupta, Vikas
    Oh, Stephen T.
    Kuykendall, Andrew T.
    Mesa, Ruben
    Kiladjian, Jean-Jacques
    Talpaz, Moshe
    Kremyanskaya, Marina
    Scandura, Joseph
    Kraeft, Tabea
    Eliane, Jean-Pierre
    Chang, Tzuu-Wang
    Cui, Jike
    Kuffer, Christian
    Boxhammer, Rainer
    Harrison, Claire
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S417 - S418
  • [28] Safety and efficacy of besifovir in treatment-naive chronic hepatitis B virus infection: a randomized, double-blind, double dummy, phase 3 study
    Ahn, S. H.
    Kim, W.
    Jung, Y. K.
    Yang, J. M.
    Jang, J. Y.
    Kweon, Y. O.
    Cho, Y. K.
    Kim, Y. J.
    Hong, G. Y.
    Kim, D. J.
    Um, S. H.
    Sohn, J. H.
    Lee, J. W.
    Park, S. J.
    Lee, B. S.
    Kim, J. H.
    Kim, H. S.
    Yoon, S. K.
    Kim, M. Y.
    Yim, H. J.
    Lee, K. S.
    Lim, Y. S.
    Lee, W. S.
    Park, N. H.
    Jin, S. Y.
    Kim, K. H.
    Han, K. H.
    JOURNAL OF HEPATOLOGY, 2017, 66 (01) : S88 - S89
  • [29] Panorama 1: A randomized, double-blind, phase 3 study of panobinostat or placebo plus bortezomib and dexamethasone in relapsed or relapsed and refractory multiple myeloma.
    Richardson, Paul G.
    Hungria, Vania T. M.
    Yoon, Sung-Soo
    Beksac, Meral
    Dimopoulos, Meletios A.
    Elghandour, Ashraf
    Jedrzejczak, Wieslaw W.
    Guenther, Andreas
    Nakorn, Thanyaphong Na
    Siritanaratkul, Noppadol
    Schlossman, Robert L.
    Hou, Jian
    Moreau, Philippe
    Lonial, Sagar
    Lee, Jae Hoon
    Einsele, Hermann
    Sopala, Monika
    Bengoudifa, Bourras-Rezki
    Corrado, Claudia
    San-Miguel, Jesus F.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [30] Long-term treatment with ruxolitinib for patients with myelofibrosis: 5-year update from the randomized, double-blind, placebo-controlled, phase 3 COMFORT-I trial
    Verstovsek, Srdan
    Mesa, Ruben A.
    Gotlib, Jason
    Gupta, Vikas
    DiPersio, John F.
    Catalano, John V.
    Deininger, Michael W. N.
    Miller, Carole B.
    Silver, Richard T.
    Talpaz, Moshe
    Winton, Elliott F.
    Harvey, Jimmie H., Jr.
    Arcasoy, Murat O.
    Hexner, Elizabeth O.
    Lyons, Roger M.
    Paquette, Ronald
    Raza, Azra
    Jones, Mark
    Kornacki, Deanna
    Sun, Kang
    Kantarjian, Hagop
    JOURNAL OF HEMATOLOGY & ONCOLOGY, 2017, 10 : 1 - 14
12345